83 related articles for article (PubMed ID: 22816666)
1. Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation.
Matz M; Lehnert M; Lorkowski C; Fabritius K; Unterwalder N; Doueiri S; Weber UA; Mashreghi MF; Neumayer HH; Budde K
Transpl Int; 2012 Oct; 25(10):1106-16. PubMed ID: 22816666
[TBL] [Abstract][Full Text] [Related]
2. Combined standard and novel immunosuppressive substances affect B-lymphocyte function.
Matz M; Lehnert M; Lorkowski C; Fabritius K; Weber UA; Mashreghi MF; Neumayer HH; Budde K
Int Immunopharmacol; 2013 Apr; 15(4):718-25. PubMed ID: 23499640
[TBL] [Abstract][Full Text] [Related]
3. Overview of sotrastaurin clinical pharmacokinetics.
Kovarik JM; Slade A
Ther Drug Monit; 2010 Oct; 32(5):540-3. PubMed ID: 20683390
[TBL] [Abstract][Full Text] [Related]
4. In vitro effects of everolimus and intravenous immunoglobulin on cell proliferation and apoptosis induction in the mixed lymphocyte reaction.
Amet N; Gacad M; Petrosyan A; Pao A; Jordan SC; Toyoda M
Transpl Immunol; 2010 Aug; 23(4):170-3. PubMed ID: 20609387
[TBL] [Abstract][Full Text] [Related]
5. Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin.
Heidt S; Roelen DL; Eijsink C; van Kooten C; Claas FH; Mulder A
Transplantation; 2008 Nov; 86(9):1292-300. PubMed ID: 19005412
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients.
Kovarik JM; Steiger JU; Grinyo JM; Rostaing L; Arns W; Dantal J; Proot P; Budde K;
Transplantation; 2011 Feb; 91(3):317-22. PubMed ID: 21157403
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.
Böhler T; Waiser J; Lichter S; Schumann B; Neumayer HH; Kamar N; Budde K
Cytokine; 2008 Jun; 42(3):306-11. PubMed ID: 18440821
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of drug action on B-cell proliferation and differentiation for mycophenolic acid, everolimus, and prednisolone.
Haneda M; Owaki M; Kuzuya T; Iwasaki K; Miwa Y; Kobayashi T
Transplantation; 2014 Feb; 97(4):405-12. PubMed ID: 24445924
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of JAK3 and PKC via Immunosuppressive Drugs Tofacitinib and Sotrastaurin Inhibits Proliferation of Human B Lymphocytes In Vitro.
Martina MN; Ramirez Bajo MJ; Bañon-Maneus E; Moya Rull D; Hierro-Garcia N; Revuelta I; Campistol JM; Rovira J; Diekmann F
Transplant Proc; 2016 Nov; 48(9):3046-3052. PubMed ID: 27932144
[TBL] [Abstract][Full Text] [Related]
10. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses.
Struijk GH; Minnee RC; Koch SD; Zwinderman AH; van Donselaar-van der Pant KA; Idu MM; ten Berge IJ; Bemelman FJ
Kidney Int; 2010 Nov; 78(9):934-40. PubMed ID: 20703211
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease.
Lietz K; John R; Burke E; Schuster M; Rogers TB; Suciu-Foca N; Mancini D; Itescu S
Circulation; 2005 Oct; 112(16):2468-76. PubMed ID: 16230499
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolic acid and intravenous immunoglobulin exert an additive effect on cell proliferation and apoptosis in the mixed lymphocyte reaction.
Sharma KG; Radha R; Pao A; Amet N; Baden L; Jordan SC; Toyoda M
Transpl Immunol; 2010 Jul; 23(3):117-20. PubMed ID: 20450974
[TBL] [Abstract][Full Text] [Related]
13. Role of FK778 alone or in combination with tacrolimus or mTOR inhibitors as an immunomodulator of immunofunctions: in vitro evaluation of T cell proliferation and the expression of lymphocyte surface antigens.
Millán O; Jiménez O; Fortuna V; Barceló JJ; Brunet M
Int J Immunopathol Pharmacol; 2006; 19(2):317-30. PubMed ID: 16831299
[TBL] [Abstract][Full Text] [Related]
14. Sotrastaurin and tacrolimus coadministration: effects on pharmacokinetics and biomarker responses.
Kovarik JM; Stitah S; Slade A; Vitaliti A; Straube F; Grenet O; Winter S; Sfikas N; Seiberling M
J Clin Pharmacol; 2010 Nov; 50(11):1260-6. PubMed ID: 20386017
[TBL] [Abstract][Full Text] [Related]
15. Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720.
Weckbecker G; Pally C; Beerli C; Burkhart C; Wieczorek G; Metzler B; Morris RE; Wagner J; Bruns C
Transpl Int; 2010 May; 23(5):543-52. PubMed ID: 20003043
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation.
Matz M; Naik M; Mashreghi MF; Glander P; Neumayer HH; Budde K
Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):103-13. PubMed ID: 21142580
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of S-adenosyl-L-homocysteine hydrolase induces immunosuppression.
Wu QL; Fu YF; Zhou WL; Wang JX; Feng YH; Liu J; Xu JY; He PL; Zhou R; Tang W; Wang GF; Zhou Y; Yang YF; Ding J; Li XY; Chen XR; Yuan C; Lawson BR; Zuo JP
J Pharmacol Exp Ther; 2005 May; 313(2):705-11. PubMed ID: 15640397
[TBL] [Abstract][Full Text] [Related]
18. Selective modulation of B-cell activation markers CD86 and I-Ak on murine draining lymph node cells following allergen or irritant treatment.
Gerberick GF; Cruse LW; Miller CM; Ridder GM
Toxicol Appl Pharmacol; 1999 Sep; 159(2):142-51. PubMed ID: 10495778
[TBL] [Abstract][Full Text] [Related]
19. Synovial fluid transforming growth factor beta inhibits dendritic cell-T lymphocyte interactions in patients with chronic arthritis.
Summers KL; O'Donnell JL; Heiser A; Highton J; Hart DN
Arthritis Rheum; 1999 Mar; 42(3):507-18. PubMed ID: 10088774
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive and autoimmune effects of thimerosal in mice.
Havarinasab S; Häggqvist B; Björn E; Pollard KM; Hultman P
Toxicol Appl Pharmacol; 2005 Apr; 204(2):109-21. PubMed ID: 15808517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
